Ampio and DMI said that the acquisition is expected to provide Ampio access to all rights, royalties and patents associated with DMI’s assets, drugs for male sexual dysfunction including premature ejaculation (PE) and combination drugs to treat premature ejaculation and erectile dysfunction (ED).
DMI’s assets have been issued patents in US and international and additional patent fillings. Ampio is also expected to receive Phase III clinical trial data accumulated for the treatment of premature ejaculation.
In the Phase II clinical trials the drug showed efficacy, safety and patient tolerability and was licensed to an international specialty pharmaceutical company which started Phase III clinical trials in Europe with its proprietary oral formulation.
DMI said that it regained ownership of the male sexual dysfunction drugs when the licensee withdrew from the latest trials due to its recent industry merger and an internal refocusing of therapeutic areas of interest.
Ampio has recently begun enrolling patients for its trial of Optina for diabetic retinopathy and has started the CRO selection process for its clinical trial programs.
Ampio said that, as soon as the terms of the acquisition agreement are approved by DMI shareholders, it will look out for licensing opportunities for its sexual dysfunction drugs.
Don Wingerter, CEO of Ampio, said: “These late stage drugs are expected to complement our existing pipeline of other repurposed drugs that require less time and expense to start clinical trials.
“As a result, we can have multiple trials running concurrently without the need for excessive capital or a drain on our personnel resources.”